Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate

World Journal of Gastroenterology

Volumn 22, Issue 32, 2016, Pages 7186-7202

  Gallo, Antonella ^a   Passaro, Giovanna ^a   Gasbarrini, Antonio ^a   Landolfi, Raffaele ^a   Montalto, Massimo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Gut; Inflammation; Microbiota; Prebiotic; Probiotic

Indexed keywords

ANTIBIOTIC AGENT; PREBIOTIC AGENT; PROBIOTIC AGENT; SYNBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC ASSOCIATED DIARRHEA; BACTERIAL COLONIZATION; ENTERITIS; EVIDENCE BASED MEDICINE; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; ILEITIS; IMMUNE RESPONSE; INFECTIOUS DIARRHEA; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; IRRITABLE COLON; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ULCERATIVE COLITIS; DIARRHEA; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; MICROBIOLOGY; ROTAVIRUS INFECTIONS;

ANTI-BACTERIAL AGENTS; DIARRHEA; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; PREBIOTICS; PROBIOTICS; ROTAVIRUS INFECTIONS;

EID: 84983535417     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i32.7186     Document Type: Review

References (204)

1. Mondot S, de Wouters T, Doré J, Lepage P. The human gut microbiome and its dysfunctions. Dig Dis 2013; 31: 278-285 [PMID: 24246975 DOI: 10.1159/000354678]
2. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 512-519 [PMID: 12583961]
3. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 2006; 124: 837-848 [PMID: 16497592]
4. Suau A, Bonnet R, Sutren M, Godon JJ, Gibson GR, Collins MD, Doré J. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol 1999; 65: 4799-4807 [PMID: 10543789]
5. Ianiro G, Bruno G, Lopetuso L, Beghella FB, Laterza L, D'Aversa F, Gigante G, Cammarota G, Gasbarrini A. Role of yeasts in healthy and impaired gut microbiota: the gut mycome. Curr Pharm Des 2014; 20: 4565-4569 [PMID: 24180411]
6. Round JL, O'Connell RM, Mazmanian SK. Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun 2010; 34: J220-J225 [PMID: 19963349]
7. Hayashi H, Sakamoto M, Benno Y. Phylogenetic analysis of the human gut microbiota using 16S rDNA clone libraries and strictly anaerobic culture-based methods. Microbiol Immunol 2002; 46: 535-548 [PMID: 12363017]
8. D'Aversa F, Tortora A, Ianiro G, Ponziani FR, Annicchiarico BE, Gasbarrini A. Gut microbiota and metabolic syndrome. Intern Emerg Med 2013; 8 Suppl 1: S11-S15 [PMID: 23468402 DOI: 10.1007/s11739-013-0916-z]
9. Cummings JH, Beatty ER, Kingman SM, Bingham SA, Englyst HN. Digestion and physiological properties of resistant starch in the human large bowel. Br J Nutr 1996; 75: 733-747 [PMID: 8695600]
10. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 1987; 28: 1221-1227 [PMID: 3678950]
11. Conly JM, Stein K, Worobetz L, Rutledge-Harding S. The contribution of vitamin K2 (menaquinones) produced by the intestinal microflora to human nutritional requirements for vitamin K. Am J Gastroenterol 1994; 89: 915-923 [PMID: 8198105]
12. Younes H, Coudray C, Bellanger J, Demigné C, Rayssiguier Y, Rémésy C. Effects of two fermentable carbohydrates (inulin and resistant starch) and their combination on calcium and magnesium balance in rats. Br J Nutr 2001; 86: 479-485 [PMID: 11591235]
13. Gordon JI, Hooper LV, McNevin MS, Wong M, Bry L. Epithelial cell growth and differentiation. III. Promoting diversity in the intestine: conversations between the microflora, epithelium, and diffuse GALT. Am J Physiol 1997; 273: G565-G570 [PMID: 9316460]
14. Srikanth CV, McCormick BA. Interactions of the intestinal epithelium with the pathogen and the indigenous microbiota: a three-way crosstalk. Interdiscip Perspect Infect Dis 2008; 2008: 626827 [PMID: 19259328 DOI: 10.1155/2008/626827]
15. Purchiaroni F, Tortora A, Gabrielli M, Bertucci F, Gigante G, Ianiro G, Ojetti V, Scarpellini E, Gasbarrini A. The role of intestinal microbiota and the immune system. Eur Rev Med Pharmacol Sci 2013; 17: 323-333 [PMID: 23426535]
16. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003; 85: 85-95 [PMID: 12527213]
17. Medzhitov R, Janeway C. Innate immune recognition: mechanisms and pathways. Immunol Rev 2000; 173: 89-97 [PMID: 10719670]
18. Tlaskalová-Hogenová H, Stepánková R, Hudcovic T, Tucková L, Cukrowska B, Lodinová-Zádníková R, Kozáková H, Rossmann P, Bártová J, Sokol D, Funda DP, Borovská D, Reháková Z, Sinkora J, Hofman J, Drastich P, Kokesová A. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett 2004; 93: 97-108 [PMID: 15158604]
19. Tlaskalová-Hogenová H, Stěpánková R, Kozáková H, Hudcovic T, Vannucci L, Tučková L, Rossmann P, Hrnčíř T, Kverka M, Zákostelská Z, Klimešová K, Přibylová J, Bártová J, Sanchez D, Fundová P, Borovská D, Srůtková D, Zídek Z, Schwarzer M, Drastich P, Funda DP. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 2011; 8: 110-120 [PMID: 21278760 DOI: 10.1038/cmi.2010.67]
20. Rescigno M, Urbano M, Valzasina B, Francolini M, Rotta G, Bonasio R, Granucci F, Kraehenbuhl JP, Ricciardi-Castagnoli P. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2001; 2: 361-367 [PMID: 11276208]
21. Kamada N, Núñez G. Role of the gut microbiota in the development and function of lymphoid cells. J Immunol 2013; 190: 1389-1395 [PMID: 23378581 DOI: 10.4049/jimmunol.1203100]
22. Schiffrin EJ, Blum S. Interactions between the microbiota and the intestinal mucosa. Eur J Clin Nutr 2002; 56 Suppl 3: S60-S64 [PMID: 12142966]
23. Quigley EM. Prebiotics and probiotics: their role in the management of gastrointestinal disorders in adults. Nutr Clin Pract 2012; 27: 195-200 [PMID: 22127952 DOI: 10.1177/0884533611423926]
24. Sartor RB, Muehlbauer M. Microbial host interactions in IBD: implications for pathogenesis and therapy. Curr Gastroenterol Rep 2007; 9: 497-507 [PMID: 18377803]
25. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Report of the Joint Food and Agriculture Organization (FAO) of the United Nations/World Health Organization (WHO) Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Cordoba: FAO/WHO, 2001
26. Andrews JM, Tan M. Probiotics in luminal gastroenterology: the current state of play. Intern Med J 2012; 42: 1287-1291 [PMID: 23252997 DOI: 10.1111/imj.12015]
27. Balakrishnan M, Floch MH. Prebiotics, probiotics and digestive health. Curr Opin Clin Nutr Metab Care 2012; 15: 580-585 [PMID: 23037903 DOI: 10.1097/MCO.0b013e328359684f]
28. Ceapa C, Wopereis H, Rezaïki L, Kleerebezem M, Knol J, Oozeer R. Influence of fermented milk products, prebiotics and probiotics on microbiota composition and health. Best Pract Res Clin Gastroenterol 2013; 27: 139-155 [PMID: 23768559 DOI: 10.1016/j.bpg.2013.04.004]
29. Boirivant M, Strober W. The mechanism of action of probiotics. Curr Opin Gastroenterol 2007; 23: 679-692 [PMID: 17906447]
30. Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004; 286: G613-G626 [PMID: 15010363]
31. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121: 580-591 [PMID: 11522742]
32. Neish AS, Gewirtz AT, Zeng H, Young AN, Hobert ME, Karmali V, Rao AS, Madara JL. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 2000; 289: 1560-1563 [PMID: 10968793]
33. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 2010; 7: 503-514 [PMID: 20664519 DOI: 10.1038/nrgastro.2010.117]
34. Ohland CL, Macnaughton WK. Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 2010; 298: G807-G819 [PMID: 20299599 DOI: 10.1152/ajpgi.00243.2009]
35. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science 2001; 292: 1115-1118 [PMID: 11352068]
36. de Jesus Raposo MF, de Morais AM, de Morais RM. Emergent Sources of Prebiotics: Seaweeds and Microalgae. Mar Drugs 2016; 14: pii E27 [PMID: 26828501 DOI: 10.3390/md14020027]
37. Mendis M, Leclerc E, Simsek S. Arabinoxylans, gut microbiota and immunity. Carbohydr Polym 2016; 139: 159-166 [PMID: 26794959 DOI: 10.1016/j.carbpol.2015.11.068]
38. Vieira AT, Teixeira MM, Martins FS. The role of probiotics and prebiotics in inducing gut immunity. Front Immunol 2013; 4: 445 [PMID: 24376446 DOI: 10.3389/fimmu.2013.00445]
39. Xu X, Xu P, Ma C, Tang J, Zhang X. Gut microbiota, host health, and polysaccharides. Biotechnol Adv 2013; 31: 318-337 [PMID: 23280014 DOI: 10.1016/j.biotechadv.2012.12.009]
40. Chung WS, Walker AW, Louis P, Parkhill J, Vermeiren J, Bosscher D, Duncan SH, Flint HJ. Modulation of the human gut microbiota by dietary fibres occurs at the species level. BMC Biol 2016; 14: 3 [PMID: 26754945 DOI: 10.1186/s12915-015-0224-3]
41. Conlon MA, Topping DL. Dietary polysaccharides and polyphenols can promote health by influencing gut microbiota populations. Food Funct 2016; 7: 1730 [PMID: 27068450 DOI: 10.1039/c6fo90009g]
42. Scott KP, Gratz SW, Sheridan PO, Flint HJ, Duncan SH. The influence of diet on the gut microbiota. Pharmacol Res 2013; 69: 52-60 [PMID: 23147033 DOI: 10.1016/j.phrs.2012.10.020]
43. Gibson PR, Rosella O, Wilson AJ, Mariadason JM, Rickard K, Byron K, Barkla DH. Colonic epithelial cell activation and the paradoxical effects of butyrate. Carcinogenesis 1999; 20: 539-544 [PMID: 10223179]
44. Wang HB, Wang PY, Wang X, Wan YL, Liu YC. Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription. Dig Dis Sci 2012; 57: 3126-3135 [PMID: 22684624 DOI: 10.1007/s10620-012-2259-4]
45. Xu X, Yang J, Ning Z, Zhang X. Lentinula edodes-derived polysaccharide rejuvenates mice in terms of immune responses and gut microbiota. Food Funct 2015; 6: 2653-2663 [PMID: 26135107 DOI: 10.1039/c5fo00689a]
46. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995; 125: 1401-1412 [PMID: 7782892]
47. Wang S, Zhu H, Lu C, Kang Z, Luo Y, Feng L, Lu X. Fermented milk supplemented with probiotics and prebiotics can effectively alter the intestinal microbiota and immunity of host animals. J Dairy Sci 2012; 95: 4813-4822 [PMID: 22916885 DOI: 10.3168/jds.2012-5426]
48. Guslandi M. Antibiotics for inflammatory bowel disease: do they work? Eur J Gastroenterol Hepatol 2005; 17: 145-147 [PMID: 15674090]
49. Scribano ML, Prantera C. Antibiotics and inflammatory bowel diseases. Dig Dis 2013; 31: 379-384 [PMID: 24246992]
50. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108: 1617-1621 [PMID: 7768364]
51. Prantera C, Berto E, Scribano ML, Falasco G. Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin. Ital J Gastroenterol Hepatol 1998; 30: 602-606 [PMID: 10076781]
52. Layer P, Andresen V. Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers' diarrhoea. Aliment Pharmacol Ther 2010; 31: 1155-1164 [PMID: 20331580 DOI: 10.1111/j.1365-2036.2010.04296.x]
53. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 2012; 9: 88-96 [PMID: 22183182 DOI: 10.1038/nrgastro.2011.244]
54. Choi HH, Cho YS. Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives. Clin Endosc 2016; 49: 257-265 [PMID: 26956193 DOI: 10.5946/ce.2015.117]
55. Borgia G, Maraolo AE, Foggia M, Buonomo AR, Gentile I. Fecal microbiota transplantation for Clostridium difficile infection: back to the future. Expert Opin Biol Ther 2015; 15: 1001-1014 [PMID: 26063385 DOI: 10.1517/14712598.2015.1045872]
56. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol 2014; 48: 693-702 [PMID: 24440934 DOI: 10.1097/MCG.0000000000000046]
57. Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol 2013; 29: 79-84 [PMID: 23041678 DOI: 10.1097/MOG.0b013e32835a4b3e]
58. Orel R, Kamhi Trop T. Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. World J Gastroenterol 2014; 20: 11505-11524 [PMID: 25206258 DOI: 10.3748/wjg.v20. i33.11505]
59. Kotlowski R, Bernstein CN, Sepehri S, Krause DO. High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 2007; 56: 669-675 [PMID: 17028128]
60. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev 2010; 90: 859-904 [PMID: 20664075 DOI: 10.1152/physrev.00045.2009]
61. Reiff C, Kelly D. Inflammatory bowel disease, gut bacteria and probiotic therapy. Int J Med Microbiol 2010; 300: 25-33 [PMID: 19800289 DOI: 10.1016/j.ijmm.2009.08.004]
62. Sheil B, Shanahan F, O'Mahony L. Probiotic effects on inflammatory bowel disease. J Nutr 2007; 137: 819S-824S [PMID: 17311981]
63. Ghosh S, van Heel D, Playford RJ. Probiotics in inflammatory bowel disease: is it all gut flora modulation? Gut 2004; 53: 620-622 [PMID: 15082574]
64. Andoh A, Fujiyama Y. Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease. World J Gastroenterol 2006; 12: 4452-4460 [PMID: 16874854 DOI: 10.3748/wjg.v12. i28.4452]
65. Sanders ME, Guarner F, Guerrant R, Holt PR, Quigley EM, Sartor RB, Sherman PM, Mayer EA. An update on the use and investigation of probiotics in health and disease. Gut 2013; 62: 787-796 [PMID: 23474420 DOI: 10.1136/gutjnl-2012-302504]
66. Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs 2012; 72: 803-823 [PMID: 22512365 DOI: 10.2165/11632710-000000000-00000]
67. Scaldaferri F, Gerardi V, Lopetuso LR, Del Zompo F, Mangiola F, Boškoski I, Bruno G, Petito V, Laterza L, Cammarota G, Gaetani E, Sgambato A, Gasbarrini A. Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. Biomed Res Int 2013; 2013: 435268 [PMID: 23991417 DOI: 10.1155/2013/435268]
68. Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, Otsuka M, Hasunuma O, Kurihara R, Iwasaki A, Arakawa Y. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004; 20: 1133-1141 [PMID: 15569116]
69. Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 2004; 10: PI126-PI131 [PMID: 15507864]
70. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009; 104: 437-443 [PMID: 19174792 DOI: 10.1038/ajg.2008.118]
71. Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, Tandon RK. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 1202-1209, 1209.e1 [PMID: 19631292 DOI: 10.1016/j.cgh.2009.07.016]
72. Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 2010; 10: 13 [PMID: 20398311 DOI: 10.1186/1472-6882-10-13]
73. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, Forti G, Morini S, Hassan C, Pistoia MA, Modeo ME, Rodino' S, D'Amico T, Sebkova L, Sacca' N, Di Giulio E, Luzza F, Imeneo M, Larussa T, Di Rosa S, Annese V, Danese S, Gasbarrini A. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010; 105: 2218-2227 [PMID: 20517305 DOI: 10.1038/ajg.2010.218]
74. Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Doubleblind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853-858 [PMID: 9354192]
75. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623 [PMID: 15479682]
76. Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, Armuzzi A, Gasbarrini G, Gasbarrini A. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 1567-1574 [PMID: 16696804]
77. Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis 2011; 5: 115-121 [PMID: 21453880 DOI: 10.1016/j.crohns.2010.11.004]
78. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305-309 [PMID: 10930365]
79. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a doubleblind, placebo-controlled trial. Gastroenterology 2003; 124: 1202-1209 [PMID: 12730861]
80. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 108-114 [PMID: 14684584]
81. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51: 405-409 [PMID: 12171964]
82. Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, Goldin B, Hartigan L, Kugathasan S, Levy J, Murray KF, Oliva-Hemker M, Rosh JR, Tolia V, Zholudev A, Vanderhoof JA, Hibberd PL. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005; 11: 833-839 [PMID: 16116318]
83. Raju KS, Wolfe CD. Is stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review. Br J Obstet Gynaecol 1992; 99: 530-531 [PMID: 1637777]
84. Van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, Fontaine F, DeVos M, Enslen M, Paintin M, Franchimont D. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis 2007; 13: 135-142 [PMID: 17206696]
85. Steed H, Macfarlane GT, Blackett KL, Bahrami B, Reynolds N, Walsh SV, Cummings JH, Macfarlane S. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. Aliment Pharmacol Ther 2010; 32: 872-883 [PMID: 20735782]
86. Sang LX, Chang B, Zhang WL, Wu XM, Li XH, Jiang M. Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. World J Gastroenterol 2010; 16: 1908-1915 [PMID: 20397271 DOI: 10.3748/wjg.v16.i15.1908]
87. Naidoo K, Gordon M, Fagbemi AO, Thomas AG, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2011; (12): CD007443 [PMID: 22161412 DOI: 10.1002/14651858.CD007443.pub2]
88. Mardini HE, Grigorian AY. Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis. Inflamm Bowel Dis 2014; 20: 1562-1567 [PMID: 24918321 DOI: 10.1097/MIB.0000000000000084]
89. Fujiya M, Ueno N, Kohgo Y. Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a metaanalysis of randomized controlled trials. Clin J Gastroenterol 2014; 7: 1-13 [PMID: 26183502 DOI: 10.1007/s12328-013-0440-8]
90. Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn' s disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis 2014; 20: 21-35 [PMID: 24280877 DOI: 10.1097/01.MIB.0000437495.30052.be]
91. Pardi DS, D'Haens G, Shen B, Campbell S, Gionchetti P. Clinical guidelines for the management of pouchitis. Inflamm Bowel Dis 2009; 15: 1424-1431 [PMID: 19685489 DOI: 10.1002/ibd.21039]
92. Elahi B, Nikfar S, Derakhshani S, Vafaie M, Abdollahi M. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci 2008; 53: 1278-1284 [PMID: 17940902]
93. Nikfar S, Darvish-Damavandi M, Abdollahi M. A review and meta-analysis of the efficacy of antibiotics and probiotics in management of pouchitis. Int J Pharmacol 2010; 6: 826-835 [DOI: 10.3923/ijP. 2010.826.835]
94. Floch MH. The power of poop: probiotics and fecal microbial transplant. J Clin Gastroenterol 2012; 46: 625-626 [PMID: 22874805 DOI: 10.1097/MCG.0b013e3182667a93]
95. Butterworth AD, Thomas AG, Akobeng AK. Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008; (3): CD006634 [PMID: 18646162 DOI: 10.1002/14651858.CD006634.pub2]
96. Rahimi R, Nikfar S, Rahimi F, Elahi B, Derakhshani S, Vafaie M, Abdollahi M. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 2008; 53: 2524-2531 [PMID: 18270836 DOI: 10.1007/s10620-007-0171-0]
97. Casellas F, Borruel N, Torrejón A, Varela E, Antolin M, Guarner F, Malagelada JR. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment Pharmacol Ther 2007; 25: 1061-1067 [PMID: 17439507]
98. Langlands SJ, Hopkins MJ, Coleman N, Cummings JH. Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel. Gut 2004; 53: 1610-1616 [PMID: 15479681]
99. Benjamin JL, Hedin CR, Koutsoumpas A, Ng SC, McCarthy NE, Hart AL, Kamm MA, Sanderson JD, Knight SC, Forbes A, Stagg AJ, Whelan K, Lindsay JO. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn' s disease. Gut 2011; 60: 923-929 [PMID: 21262918 DOI: 10.1136/gut.2010.232025]
100. Bamba T, Kanauchi O, Andoh A, Fujiyama Y. A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. J Gastroenterol Hepatol 2002; 17: 818-824 [PMID: 12164955]
101. Preidis GA, Versalovic J. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 2009; 136: 2015-2031 [PMID: 19462507]
102. Chermesh I, Tamir A, Reshef R, Chowers Y, Suissa A, Katz D, Gelber M, Halpern Z, Bengmark S, Eliakim R. Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. Dig Dis Sci 2007; 52: 385-389 [PMID: 17211699]
103. Leach ST, Mitchell HM, Eng WR, Zhang L, Day AS. Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn's disease. Aliment Pharmacol Ther 2008; 28: 724-733 [PMID: 19145728]
104. Tjellström B, Högberg L, Stenhammar L, Magnusson KE, Midtvedt T, Norin E, Sundqvist T. Effect of exclusive enteral nutrition on gut microflora function in children with Crohn' s disease. Scand J Gastroenterol 2012; 47: 1454-1459 [PMID: 23016828 DOI: 10.3109/00365521.2012.703234]
105. Isaacs KL, Sartor RB. Treatment of inflammatory bowel disease with antibiotics. Gastroenterol Clin North Am 2004; 33: 335-45, x [PMID: 15177542]
106. Dickinson RJ, O'Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985; 26: 1380-1384 [PMID: 3910524]
107. Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Brzezinski A, Bevins CL, Bambrick ML, Seidner DL, Fazio VW. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001; 7: 301-305 [PMID: 11720319]
108. Blichfeldt P, Blomhoff JP, Myhre E, Gjone E. Metronidazole in Crohn's disease. A double blind cross-over clinical trial. Scand J Gastroenterol 1978; 13: 123-127 [PMID: 345410]
109. Ambrose NS, Allan RN, Keighley MR, Burdon DW, Youngs D, Barnes P, Lennard-Jones JE. Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study. Dis Colon Rectum 1985; 28: 81-85 [PMID: 3882364]
110. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R, Mekhjian H, Greenberger N, Kelly M. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32: 1071-1075 [PMID: 1916494]
111. Turunen U, Farkkila M, Hakala K, Seppälä K, Sivonen A, Ogren M, Vuoristo M, Valtonen VV, Miettinen TA. Ciprofloxacin treatment combined with conventional therapy in Crohn's disease: a prospective, double blind, placebo controlled study. Gut 1995; 37: A193
112. Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, Luzi C. An antibiotic regimen for the treatment of active Crohn' s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91: 328-332 [PMID: 8607501]
113. Colombel JF, Lémann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL, Notteghem B, Mary JY. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn' s disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999; 94: 674-678 [PMID: 10086650]
114. Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002; 8: 10-15 [PMID: 11837933]
115. Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, Seidman E, Leddin DJ, Bitton A, Drouin E, Cohen A, Greenberg GR. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002; 123: 33-40 [PMID: 12105831]
116. Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, Talley NJ, Moayyedi P. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 661-673 [PMID: 21407187 DOI: 10.1038/ajg.2011.72]
117. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, Danese S, D'Hoore A, Gassull M, Gomollón F, Hommes DW, Michetti P, O'Morain C, Oresland T, Windsor A, Stange EF, Travis SP. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010; 4: 28-62 [PMID: 21122489 DOI: 10.1016/j.crohns.2009.12.002]
118. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W, Lee CH. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology 2015; 149: 102-109.e6 [PMID: 25857665 DOI: 10.1053/j.gastro.2015.04.001]
119. Wei Y, Zhu W, Gong J, Guo D, Gu L, Li N, Li J. Fecal Microbiota Transplantation Improves the Quality of Life in Patients with Inflammatory Bowel Disease. Gastroenterol Res Pract 2015; 2015: 517597 [PMID: 26146498 DOI: 10.1155/2015/517597]
120. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2004; (2): CD003048 [PMID: 15106189]
121. Szajewska H, Kotowska M, Mrukowicz JZ, Armańska M, Mikołajczyk W. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr 2001; 138: 361-365 [PMID: 11241043]
122. Mastretta E, Longo P, Laccisaglia A, Balbo L, Russo R, Mazzaccara A, Gianino P. Effect of Lactobacillus GG and breastfeeding in the prevention of rotavirus nosocomial infection. J Pediatr Gastroenterol Nutr 2002; 35: 527-531 [PMID: 12394379]
123. Szajewska H, Wanke M, Patro B. Meta-analysis: the effects of Lactobacillus rhamnosus GG supplementation for the prevention of healthcare-associated diarrhoea in children. Aliment Pharmacol Ther 2011; 34: 1079-1087 [PMID: 21899584 DOI: 10.1111/j.1365-2036.2011.04837.x]
124. Szajewska H, Skórka A, Ruszczyński M, Gieruszczak-Białek D. Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children-updated analysis of randomised controlled trials. Aliment Pharmacol Ther 2013; 38: 467-476 [PMID: 23841880 DOI: 10.1111/apt.12403]
125. Salari P, Nikfar S, Abdollahi M. A meta-analysis and systematic review on the effect of probiotics in acute diarrhea. Inflamm Allergy Drug Targets 2012; 11: 3-14 [PMID: 22309079]
126. Mihatsch WA, Vossbeck S, Eikmanns B, Hoegel J, Pohlandt F. Effect of Bifidobacterium lactis on the incidence of nosocomial infections in very-low-birth-weight infants: a randomized controlled trial. Neonatology 2010; 98: 156-163 [PMID: 20234140 DOI: 10.1159/000280291]
127. Honeycutt TC, El Khashab M, Wardrop RM, McNeal-Trice K, Honeycutt AL, Christy CG, Mistry K, Harris BD, Meliones JN, Kocis KC. Probiotic administration and the incidence of nosocomial infection in pediatric intensive care: a randomized placebo-controlled trial. Pediatr Crit Care Med 2007; 8: 452-458; quiz 464 [PMID: 17693918]
128. Binns CW, Lee AH, Harding H, Gracey M, Barclay DV. The CUPDAY Study: prebiotic-probiotic milk product in 1-3-yearold children attending childcare centres. Acta Paediatr 2007; 96: 1646-1650 [PMID: 17937689]
129. Paredes-Paredes M, Flores-Figueroa J, Dupont HL. Advances in the treatment of travelers' diarrhea. Curr Gastroenterol Rep 2011; 13: 402-407 [PMID: 21773708 DOI: 10.1007/s11894-011-0208-6]
130. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002; 346: 334-339 [PMID: 11821511]
131. Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, Johnsen B, Shekelle PG. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012; 307: 1959-1969 [PMID: 22570464 DOI: 10.1001/jama.2012.3507]
132. Szajewska H, Kołodziej M. Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibioticassociated diarrhoea in children and adults. Aliment Pharmacol Ther 2015; 42: 1149-1157 [PMID: 26365389 DOI: 10.1111/apt.13404]
133. Hickson M, D'Souza AL, Muthu N, Rogers TR, Want S, Rajkumar C, Bulpitt CJ. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007; 335: 80 [PMID: 17604300]
134. Ehrhardt S, Guo N, Hinz R, Schoppen S, May J, Reiser M, Schroeder MP, Schmiedel S, Keuchel M, Reisinger EC, Langeheinecke A, de Weerth A, Schuchmann M, Schaberg T, Ligges S, Eveslage M, Hagen RM, Burchard GD, Lohse AW. Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. Open Forum Infect Dis 2016; 3: ofw011 [PMID: 26973849 DOI: 10.1093/ofid/ofw011]
135. Allen SJ, Wareham K, Wang D, Bradley C, Hutchings H, Harris W, Dhar A, Brown H, Foden A, Gravenor MB, Mack D. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2013; 382: 1249-1257 [PMID: 23932219 DOI: 10.1016/S0140-6736(13)61218-0]
136. Xie C, Li J, Wang K, Li Q, Chen D. Probiotics for the prevention of antibiotic-associated diarrhoea in older patients: a systematic review. Travel Med Infect Dis 2015; 13: 128-134 [PMID: 25805164 DOI: 10.1016/j.tmaid.2015.03.00]
137. Szajewska H, Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2015; 42: 793-801 [PMID: 26216624 DOI: 10.1111/apt.13344]
138. Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, Moore T, Wu G. Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology 2015; 149: 223-237 [PMID: 25982290 DOI: 10.1053/j.gastro.2015.05.008]
139. Johnston BC, Goldenberg JZ, Guyatt GH. Probiotics for the prevention of Clostridium difficile-associated diarrhea. In response. Ann Intern Med 2013; 158: 706-707 [PMID: 23648957 DOI: 10.7326/0003-4819-158-9-201305070-00019]
140. Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol 2005; 3: 442-448 [PMID: 15880313]
141. Orrhage K, Sjöstedt S, Nord CE. Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil. J Antimicrob Chemother 2000; 46: 603-612 [PMID: 11020259]
142. Gupta S, Allen-Vercoe E, Petrof EO. Fecal microbiota transplantation: in perspective. Therap Adv Gastroenterol 2016; 9: 229-239 [PMID: 26929784 DOI: 10.1177/1756283X15607414]
143. Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, Kelly C, Park T, Stollman N, Rohlke F, Surawicz C. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107: 1079-1087 [PMID: 22450732 DOI: 10.1038/ajg.2012.60]
144. Jeffery IB, Quigley EM, Öhman L, Simrén M, O'Toole PW. The microbiota link to irritable bowel syndrome: an emerging story. Gut Microbes 2012; 3: 572-576 [PMID: 22895081 DOI: 10.4161/gmic.21772]
145. Tojo R, Suárez A, Clemente MG, de los Reyes-Gavilán CG, Margolles A, Gueimonde M, Ruas-Madiedo P. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol 2014; 20: 15163-15176 [PMID: 25386066 DOI: 10.3748/wjg.v20.i41.15163]
146. Eutamene H, Lamine F, Chabo C, Theodorou V, Rochat F, Bergonzelli GE, Corthésy-Theulaz I, Fioramonti J, Bueno L. Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats. J Nutr 2007; 137: 1901-1907 [PMID: 17634262]
147. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebocontrolled crossover study. Dig Liver Dis 2000; 32: 294-301 [PMID: 11515626]
148. Nobaek S, Johansson ML, Molin G, Ahrné S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 1231-1238 [PMID: 10811333]
149. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoeapredominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 895-904 [PMID: 12656692]
150. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551 [PMID: 15765388]
151. Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005; 22: 387-394 [PMID: 16128676]
152. Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G, Zinsmeister AR. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005; 17: 687-696 [PMID: 16185307]
153. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome-a double blind, placebo-controlled, randomized study. Clin Nutr 2005; 24: 925-931 [PMID: 16051399]
154. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581-1590 [PMID: 16863564]
155. Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, Matuchansky C. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the healthrelated quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007; 26: 475-486 [PMID: 17635382]
156. Kajander K, Myllyluoma E, Rajilić-Stojanović M, Kyrönpalo S, Rasmussen M, Järvenpää S, Zoetendal EG, de Vos WM, Vapaatalo H, Korpela R. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008; 27: 48-57 [PMID: 17919270]
157. Zeng J, Li YQ, Zuo XL, Zhen YB, Yang J, Liu CH. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2008; 28: 994-1002 [PMID: 18671775 DOI: 10.1111/j.1365-2036.2008.03818.x]
158. Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol 2008; 32: 147-152 [PMID: 18387426 DOI: 10.1016/j.gcB.2007.06.001]
159. Sinn DH, Song JH, Kim HJ, Lee JH, Son HJ, Chang DK, Kim YH, Kim JJ, Rhee JC, Rhee PL. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008; 53: 2714-2718 [PMID: 18274900 DOI: 10.1007/s10620-007-0196-4]
160. Simrén M, Ohman L, Olsson J, Svensson U, Ohlson K, Posserud I, Strid H. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome - a randomized, double-blind, controlled study. Aliment Pharmacol Ther 2010; 31: 218-227 [PMID: 19863495 DOI: 10.1111/j.1365-2036.2009.04183.x]
161. Søndergaard B, Olsson J, Ohlson K, Svensson U, Bytzer P, Ekesbo R. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial. Scand J Gastroenterol 2011; 46: 663-672 [PMID: 21443416 DOI: 10.3109/00365521.2011.565]
162. Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life-a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011; 33: 1123-1132 [PMID: 21418261 DOI: 10.1111/j.1365-2036.2011.04633.x]
163. Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol 2012; 18: 4012-4018 [PMID: 22912552 DOI: 10.3748/wjg.v18.i30.4012]
164. Kruis W, Chrubasik S, Boehm S, Stange C, Schulze J. A doubleblind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis 2012; 27: 467-474 [PMID: 22130826 DOI: 10.1007/s00384-011-1363-9]
165. Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol 2012; 46: 220-227 [PMID: 22157240 DOI: 10.1097/MCG.0b013e31823712b1]
166. Dapoigny M, Piche T, Ducrotte P, Lunaud B, Cardot JM, Bernalier-Donadille A. Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: a randomized, double-blind study. World J Gastroenterol 2012; 18: 2067-2075 [PMID: 22563194 DOI: 10.3748/wjg.v18.i17.2067]
167. Roberts LM, McCahon D, Holder R, Wilson S, Hobbs FD. A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome. BMC Gastroenterol 2013; 13: 45 [PMID: 23496803 DOI: 10.1186/1471-230X-13-45]
168. Shavakhi A, Minakari M, Farzamnia S, Peykar MS, Taghipour G, Tayebi A, Hashemi H, Shavakhi S. The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial. Adv Biomed Res 2014; 3: 140 [PMID: 25161987 DOI: 10.410 3/2277-9175.135157]
169. Yoon H, Park YS, Lee DH, Seo JG, Shin CM, Kim N. Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Biochem Nutr 2015; 57: 129-134 [PMID: 26388670 DOI: 10.3164/jcbn.15-14]
170. Pineton de Chambrun G, Neut C, Chau A, Cazaubiel M, Pelerin F, Justen P, Desreumaux P. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig Liver Dis 2015; 47: 119-124 [PMID: 25488056 DOI: 10.1016/j.dld.2014.11.007]
171. Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 2008; 51: 1775-1780 [PMID: 18465170 DOI: 10.1007/s10350-008-9335-z]
172. Hungin AP, Mulligan C, Pot B, Whorwell P, Agréus L, Fracasso P, Lionis C, Mendive J, Philippart de Foy JM, Rubin G, Winchester C, de Wit N. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidencebased international guide. Aliment Pharmacol Ther 2013; 38: 864-886 [PMID: 23981066 DOI: 10.1111/apt.12460]
173. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010; 59: 325-332 [PMID: 19091823 DOI: 10.1136/gut.2008.167270]
174. Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol 2015; 21: 3072-3084 [PMID: 25780308 DOI: 10.3748/wjg.v21.i10.3072]
175. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009; 104: 1033-1049; quiz 1050 [PMID: 19277023 DOI: 10.1038/ajg.2009.25]
176. Ligaarden SC, Axelsson L, Naterstad K, Lydersen S, Farup PG. A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. BMC Gastroenterol 2010; 10: 16 [PMID: 20144246 DOI: 10.1186/1471-230X-10-16]
177. Whelan K, Quigley EM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol 2013; 29: 184-189 [PMID: 23286925 DOI: 10.1097/MOG.0b013e32835d7bba]
178. McKenzie YA, Alder A, Anderson W, Wills A, Goddard L, Gulia P, Jankovich E, Mutch P, Reeves LB, Singer A, Lomer MC; Gastroenterology Specialist Group of the British Dietetic Association. British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults. J Hum Nutr Diet 2012; 25: 260-274 [PMID: 22489905 DOI: 10.1111/j.1365-277X.2012.01242.x]
179. Whelan K. Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care 2011; 14: 581-587 [PMID: 21892075 DOI: 10.1097/MCO.0b013e32834b8082]
180. Depeint F, Tzortzis G, Vulevic J, I'anson K, Gibson GR. Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 41171, in healthy humans: a randomized, double-blind, crossover, placebo-controlled intervention study. Am J Clin Nutr 2008; 87: 785-791 [PMID: 18326619]
181. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29: 508-518 [PMID: 19053980 DOI: 10.1111/j.1365-2036.2008.03911.x]
182. Andriulli A, Neri M, Loguercio C, Terreni N, Merla A, Cardarella MP, Federico A, Chilovi F, Milandri GL, De Bona M, Cavenati S, Gullini S, Abbiati R, Garbagna N, Cerutti R, Grossi E. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study. J Clin Gastroenterol 2008; 42 Suppl 3 Pt 2: S218-S223 [PMID: 18685503 DOI: 10.1097/MCG.0b013e31817fadd6]
183. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32 [PMID: 21208106 DOI: 10.1056/NEJMoa1004409]
184. Sears CL, Pardoll DM. Perspective: alpha-bugs, their microbial partners, and the link to colon cancer. J Infect Dis 2011; 203: 306-311 [PMID: 21208921 DOI: 10.1093/jinfdis/jiq061]
185. Ishikawa H, Akedo I, Otani T, Suzuki T, Nakamura T, Takeyama I, Ishiguro S, Miyaoka E, Sobue T, Kakizoe T. Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumors. Int J Cancer 2005; 116: 762-767 [PMID: 15828052]
186. Peitsidou K, Karantanos T, Theodoropoulos GE. Probiotics, prebiotics, synbiotics: is there enough evidence to support their use in colorectal cancer surgery?. Dig Surg 2012; 29: 426-438 [PMID: 23258276 DOI: 10.1159/000345580]
187. Delia P, Sansotta G, Donato V, Frosina P, Salatino A, Messina G, De Renzis C, Famularo G. Use of probiotics for prevention of radiation-induced diarrhea. Tumori 2007; 93: suppl 1-6 [PMID: 17557582]
188. Demers M, Dagnault A, Desjardins J. A randomized doubleblind controlled trial: impact of probiotics on diarrhea in patients treated with pelvic radiation. Clin Nutr 2014; 33: 761-767 [PMID: 24200199 DOI: 10.1016/j.clnu.2013.10.015]
189. Visich KL, Yeo TP. The prophylactic use of probiotics in the prevention of radiation therapy-induced diarrhea. Clin J Oncol Nurs 2010; 14: 467-473 [PMID: 20682502 DOI: 10.1188/10. CJON.467-473]
190. Wedlake LJ, Shaw C, Whelan K, Andreyev HJ. Systematic review: the efficacy of nutritional interventions to counteract acute gastrointestinal toxicity during therapeutic pelvic radiotherapy. Aliment Pharmacol Ther 2013; 37: 1046-1056 [PMID: 23611411 DOI: 10.1111/apt.12316]
191. Stein K, Borowicki A, Scharlau D, Schettler A, Scheu K, Obst U, Glei M. Effects of synbiotic fermentation products on primary chemoprevention in human colon cells. J Nutr Biochem 2012; 23: 777-784 [PMID: 21840698 DOI: 10.1016/j.jnutbio.2011.03.022]
192. Compare D, Nardone G. The role of gut microbiota in the pathogenesis and management of allergic diseases. Eur Rev Med Pharmacol Sci 2013; 17 Suppl 2: 11-17 [PMID: 24443062]
193. Hardy H, Harris J, Lyon E, Beal J, Foey AD. Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology. Nutrients 2013; 5: 1869-1912 [PMID: 23760057 DOI: 10.3390/nu5061869]
194. Kuitunen M. Probiotics and prebiotics in preventing food allergy and eczema. Curr Opin Allergy Clin Immunol 2013; 13: 280-286 [PMID: 23594506 DOI: 10.1097/ACI.0b013e328360ed66]
195. Fiocchi A, Burks W, Bahna SL, Bielory L, Boyle RJ, Cocco R, Dreborg S, Goodman R, Kuitunen M, Haahtela T, Heine RG, Lack G, Osborn DA, Sampson H, Tannock GW, Lee BW. Clinical Use of Probiotics in Pediatric Allergy (CUPPA): A World Allergy Organization Position Paper. World Allergy Organ J 2012; 5: 148-167 [PMID: 23282383 DOI: 10.1097/WOX.0b013e3182784ee0]
196. Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 1997; 112: 109-117 [PMID: 8978349]
197. Lanas A, Scarpignato C. Microbial flora in NSAID-induced intestinal damage: a role for antibiotics? Digestion 2006; 73 Suppl 1: 136-150 [PMID: 16498262]
198. Scarpignato C. NSAID-induced intestinal damage: are luminal bacteria the therapeutic target? Gut 2008; 57: 145-148 [PMID: 18192448 DOI: 10.1136/gut.2007.134502]
199. Wallace JL. Prevention of NSAID-Enteropathy: A Soluble Problem? Dig Dis Sci 2016; 61: 1-3 [PMID: 26576552 DOI: 10.1007/s10620-015-3963-7]
200. Montalto M, Maggiano N, Ricci R, Curigliano V, Santoro L, Di Nicuolo F, Vecchio FM, Gasbarrini A, Gasbarrini G. Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells. Digestion 2004; 69: 225-228 [PMID: 15205571]
201. Montalto M, Gallo A, Gasbarrini A, Landolfi R. NSAID enteropathy: could probiotics prevent it? J Gastroenterol 2013; 48: 689-697 [PMID: 22875474 DOI: 10.1007/s00535-012-0648-2]
202. Gotteland M, Cruchet S, Verbeke S. Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indometacin in humans. Aliment Pharmacol Ther 2001; 15: 11-17 [PMID: 11136273]
203. Montalto M, Gallo A, Curigliano V, D'Onofrio F, Santoro L, Covino M, Dalvai S, Gasbarrini A, Gasbarrini G. Clinical trial: the effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy - a randomized, double-blind, cross-over, placebocontrolled study. Aliment Pharmacol Ther 2010; 32: 209-214 [PMID: 20384610 DOI: 10.1111/j.1365-2036.2010.04324.x]
204. Endo H, Higurashi T, Hosono K, Sakai E, Sekino Y, Iida H, Sakamoto Y, Koide T, Takahashi H, Yoneda M, Tokoro C, Inamori M, Abe Y, Nakajima A. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol 2011; 46: 894-905 [PMID: 21556830 DOI: 10.1007/s00535-011-0410-1]